In parallel, bispecific antibodies targeting two immune checkpoints, such as PD-1 or CTLA-4, are currently under development, and will be tested in clinical trials enrolling patients with different cancers, including EC and CC (NCT03517488) [160,161]. Here, CTLA4 is linked to cancer.